GlucoTrack 과거 수익 실적

과거 기준 확인 0/6

GlucoTrack의 수입은 연평균 -1%의 비율로 감소해 온 반면, Medical Equipment 산업은 수입이 연평균 12%의 비율로 증가했습니다. 매출은 연평균 91.9%의 비율로 감소해 왔습니다.

주요 정보

-1.0%

수익 성장률

29.2%

EPS 성장률

Medical Equipment 산업 성장	8.9%
매출 성장률	-91.9%
자기자본 수익률	n/a
순이익	n/a
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

GlucoTrack to start R&D program for glucose monitoring system

Oct 10

수익 및 비용 분석

GlucoTrack 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:GCTK 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	0	-15	4	10
30 Jun 24	0	-12	3	9
31 Mar 24	0	-10	3	6
31 Dec 23	0	-8	2	5
30 Sep 23	0	-7	2	4
30 Jun 23	0	-6	2	2
31 Mar 23	0	-5	2	2
31 Dec 22	0	-4	2	2
30 Sep 22	0	-5	3	2
30 Jun 22	0	-5	2	2
31 Mar 22	0	-4	2	2
31 Dec 21	0	-4	2	2
30 Sep 21	0	-3	2	1
30 Jun 21	0	-3	2	1
31 Mar 21	0	-3	2	1
31 Dec 20	0	-3	2	1
30 Sep 20	0	-2	1	2
30 Jun 20	0	-3	1	2
31 Mar 20	0	-3	2	2
31 Dec 19	0	-4	2	2
30 Sep 19	0	-35	2	2
30 Jun 19	0	-37	2	3
31 Mar 19	0	-38	3	3
31 Dec 18	0	-40	4	3
30 Sep 18	1	-11	6	3
30 Jun 18	1	-11	7	3
31 Mar 18	1	-11	7	3
31 Dec 17	1	-12	8	3
30 Sep 17	0	-10	7	2
30 Jun 17	0	-9	5	2
31 Mar 17	1	-8	4	3
31 Dec 16	1	-6	3	3
30 Sep 16	0	-6	3	3
30 Jun 16	0	-6	3	3
31 Mar 16	0	-6	3	2
31 Dec 15	0	-6	2	2
30 Sep 15	0	-5	2	2
30 Jun 15	0	-5	2	2
31 Mar 15	0	1	2	2
31 Dec 14	0	2	2	2
30 Sep 14	0	-5	2	2
30 Jun 14	0	-5	1	2
31 Mar 14	0	-10	1	2

양질의 수익: GCTK 은(는) 현재 수익성이 없습니다.

이익 마진 증가: GCTK 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: GCTK 은(는) 수익성이 없으며 지난 5년 동안 연간 1% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 GCTK 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: GCTK 은(는) 수익성이 없어 지난 해 수익 성장을 Medical Equipment 업계( 10.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: GCTK 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

GlucoTrack 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Recent updates

GlucoTrack, Inc. has completed a Follow-on Equity Offering in the amount of $9.995237 million.

Glucotrack, Inc. Appoints John Ballantyne to Its Board of Directors

GlucoTrack, Inc. announced that it has received $0.1 million in funding

Glucotrack Announces the Appointment of Andy Balo to Board of Directors

Glucotrack Reports Successful Completion of First Reported Long-Term Preclinical Study of Its Epidural Glucose Monitoring Sensor

Glucotrack, Inc Announces 90-Day Preclinical Study Results That Demonstrate Sustained Accuracy of Its Implantable Continuous Blood Glucose Monitor

GlucoTrack Receives a Third Letter from Nasdaq Notifies Not Regains Compliance with the Minimum Bid Price Requirement During the Extended Compliance Period

Glucotrack’s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study

Glucotrack Announces Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Requirement

GlucoTrack, Inc. announced that it has received $0.5 million in funding

GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring

Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor

GlucoTrack, Inc., Annual General Meeting, Apr 26, 2024

Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors

GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor

GlucoTrack, Inc. Announces Executive Changes

Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee

Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor

GlucoTrack Receives Letter from Nasdaq Regarding No Longer Complies with Nasdaq's Listing Rule 5550(a)(2)

Nasdaq Issues a Letter to GlucoTrack Granting an Extension Until May 22, 2023 to Obtain Compliance

Glucotrack to Begin Research & Development of Novel Continuous Glucose Monitoring System

GlucoTrack to start R&D program for glucose monitoring system

GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor

Shalom Shushan, Chief Technology Officer, Provides Notice of His Resignation from Glucotrack, Inc., Effective May 22, 2022

Integrity Applications, Inc. announced delayed 10-Q filing

Integrity Applications, Inc. announced delayed annual 10-K filing

Integrity Applications, Inc. Announces Executive Changes

Integrity Applications Appoints Paul V. Goode to Board of Directors

Integrity Applications, Inc. Appoints Shalom Shushan as Chief Technology Officer, Effective November 9, 2020

Integrity Applications, Inc. Announces Resignation of Eugene Naidis as Vice President of R&D, Effective December 31, 2020

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기